Teva Bows To $1.4bn US Ingrezza IP With Far Future Settlement
Israeli Firm Must Wait To Broaden TD Portfolio With Distant Settlement Deal
Executive Summary
Teva has found a settlement deal with Neurocrine over the TD blockbuster Ingrezza.
Topics
- Subjects
- Intellectual Property
- Legal Issues
- Deals
- Generic Drugs
- Regions
- North America
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GB152635
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
GB152635
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.